An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function.

Trial Profile

An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Trebananib (Primary) ; Paclitaxel
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 11 Jan 2017 Results published in the Clinical Pharmacology and Therapeutics journal.
    • 06 Feb 2014 Status changed to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top